CLAIMS

1. A bispecific antibody comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20;

(a) wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) comprising the amino acid sequences of SEQ ID NOs: 1252, 1254 and 1256, respectively, and a light chain variable region (LCVR) comprising three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3) comprising the amino acid sequences of SEQ ID NO: 1260, 1262 and 1264, respectively; and wherein the second antigen-binding domain comprises a HCVR comprising three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) comprising the amino acid sequences of SEQ ID NO: 1244, 1246 and 1248, respectively, and a LCVR comprising three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3) comprising the amino acid sequences of SEQ ID NO: 1260, 1262 and 1264, respectively; or

(b) wherein the first antigen-binding domain comprises a HCVR comprising three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) comprising the amino acid sequences of SEQ ID NOs: 1268, 1270 and 1272, respectively, and a LCVR comprising three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3) comprising the amino acid sequences of SEQ ID NO: 1276, 1278 and 1280, respectively; and wherein the second antigen-binding domain comprises a HCVR comprising three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) comprising the amino acid sequences of SEQ ID NO: 1244, 1246 and 1248, respectively, and a LCVR comprising three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3) comprising the amino acid sequences of SEQ ID NO: 1276, 1278 and 1280, respectively; and

wherein the bispecific antibody induces human T-cell proliferation and monkey T-cell proliferation *in vitro*.

2. The bispecific antibody of claim 1, wherein A1-HCDR1, A1-HCDR2 and A1-HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1252, 1254 and 1256, respectively, A1-LCDR1, A1-LCDR2 and A1-LCDR3 comprise the amino acid sequences of SEQ ID NO: 1260, 1262 and 1264, respectively, A2-HCDR1, A2-HCDR2 and A2-HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1244, 1246 and 1248, respectively, and A2-LCDR1, A2-LCDR2 and A2-LCDR3 comprise the amino acid sequences of SEQ ID NO: 1260, 1262 and 1264, respectively.

3. The bispecific antibody of claim 2, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1250, and a LCVR comprising the amino acid sequence of SEQ ID NO:1258; and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1242, and a LCVR comprising the amino acid sequence of SEQ ID NO:1258.

4. The bispecific antibody of claim 1, wherein A1-HCDR1, A1-HCDR2 and A1-HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1268, 1270 and 1272, respectively, A1-LCDR1, A1-LCDR2 and A1-LCDR3 comprise the amino acid sequences of SEQ ID NO: 1276, 1278 and 1280, respectively, A2-HCDR1, A2-HCDR2 and A2-HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1244, 1246 and 1248, respectively, and A2-LCDR1, A2-LCDR2 and A2-LCDR3 comprise the amino acid sequences of SEQ ID NO: 1276, 1278 and 1280, respectively.

5. The bispecific antibody of claim 4, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1266, and a LCVR comprising the amino acid sequence of SEQ ID NO:1274; and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1242, and a LCVR comprising the amino acid sequence of SEQ ID NO:1274.

6. The bispecific antibody of claim 2, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1282, and a LCVR comprising the amino acid sequence of SEQ ID NO:1290; and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1242, and a LCVR comprising the amino acid sequence of SEQ ID NO:1290.

7. A pharmaceutical composition comprising a bispecific antibody of any one of claims 1 to 6, and a pharmaceutically acceptable carrier or diluent.

8. Use of the bispecific antibody of any one of claims 1-6, or the pharmaceutical composition of claim 7 in the manufacture of a medicament for treating a B-cell cancer in a subject.

9. The use of claim 8, wherein the B-cell cancer is selected from the group consisting of: follicular lymphoma, B cell chronic lymphocytic leukemia, B cell lymphoblastic lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma, diffuse large B cell lymphoma, marginal zone lymphoma, mantle cell lymphoma, hairy cell leukemia and Burkitt lymphoma.

10. The use of claim 9, wherein the B-cell cancer is follicular lymphoma.

11. The use of claim 9, wherein the B-cell cancer is diffuse large B cell lymphoma.

12. The use of claim 9, wherein the B-cell cancer is marginal zone lymphoma.

13. The use of claim 9, wherein the B-cell cancer is mantle cell lymphoma.

14. The use of any one of claims 8 to 13, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone.

15. The use of claim 14, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to rituximab monotherapy.

16. The use of any one of claims 8 to 15, wherein the subject has received an anti-CD20 monospecific antibody therapy at least 1 day to 1 year prior to the administration of the pharmaceutical composition.

17. The use of claim 16, wherein the anti-CD20 monospecific therapy comprises or consists of an anti-CD20 mono-specific antibody.

18. The use of claim 17, wherein the anti-CD20 mono-specific antibody is rituximab.

19. Use of the bispecific antibody of any one of claims 1-6, or the pharmaceutical composition of claim 7 in the manufacture of a medicament for treating a B-cell cancer in a subject, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone, and wherein the medicament is formulated for administration to the subject.

20. The use of claim 19, wherein the subject is selected on the basis of having a tumor that is resistant to, refractory to, or incompletely responsive to rituximab monotherapy.